Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease

Mol Cell Biochem. 2021 Feb;476(2):619-631. doi: 10.1007/s11010-020-03931-3. Epub 2020 Oct 17.

Abstract

Parkinson's disease (PD) is a disorder characterized by a progressive loss of the dopaminergic neurons in the substantia nigra and a depletion of the neurotransmitter dopamine in the striatum. Our published results indicate that fasciculation and elongation protein zeta-1 (FEZ1) plays a role in the astrocyte-mediated protection of dopamine neurons and regulation of the neuronal microenvironment during the progression of PD. In this study, we examined the effects of engrafted type-2 astrocytes (T2As) with high expression of FEZ1 on the improvement of the symptoms and functional reconstruction of PD rats. T2As were stereotactically transplanted into the striatum of rats with PD induced by 6-hydroxydopamine (6-OHDA). An examination of apomorphine (APO)-induced rotations was performed to evaluate dopamine neuron damage and motor functions. Remarkably, the grafted cells survived in the lesion environment for six weeks or longer after implantation. In addition, the transplantation of T2As decrease the average velocity and the duration time of the APO-induced rotations, and increase the actuation time, as measured in the rotation behavioural tests. In the substantia nigra, the transplantation of T2As reduced the PD-induced GFAP, TH and FEZ1 downregulation. The grafted cells exclusively migrated to other regions near the injection site in the striatum and differentiated into GFAP+ astrocytes or TH+ neurons. Furthermore, by detecting monoamine neurotransmitters through high-performance liquid chromatography, we found that the nigrostriatal pathway had been repaired to some extent. Taken together, these results suggest that engrafted T2As with high expression of FEZ1 improved the symptoms and functional reconstruction of PD rats, providing a theoretical basis for FEZ1 as a potential target and engraftment of T2As as a therapeutic strategy in the treatment of PD.

Keywords: FEZ1; Monoamine neurotransmitter; Nigrostriatal pathway; Parkinson’s disease; Type-2 astrocytes.

MeSH terms

  • Adaptor Proteins, Signal Transducing / metabolism*
  • Adrenergic Agents / administration & dosage
  • Animals
  • Apomorphine / pharmacology*
  • Astrocytes / cytology
  • Astrocytes / metabolism
  • Astrocytes / transplantation*
  • Disease Models, Animal
  • Dopaminergic Neurons / drug effects*
  • Dopaminergic Neurons / metabolism
  • Male
  • Motor Activity / drug effects
  • Oxidopamine / administration & dosage
  • Parkinson Disease / etiology
  • Parkinson Disease / metabolism
  • Parkinson Disease / pathology
  • Parkinson Disease / therapy*
  • Rats
  • Rats, Sprague-Dawley
  • Substantia Nigra / metabolism*

Substances

  • Adaptor Proteins, Signal Transducing
  • Adrenergic Agents
  • Fez1 protein, rat
  • Oxidopamine
  • Apomorphine